Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.58 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 6/20 | 0.47 |
| ▸ | MAOA | P21397 | 6/20 | 0.47 |
| ▸ | KDM1B | Q8NB78 | 6/20 | 0.47 |
| ▸ | RCOR1 | Q9UKL0 | 6/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2636659 | 0.85 | MCHR1 (0.52) | HDAC3HDAC11HDAC8HDAC6DEGS1 | |
| SCHEMBL2636432 | 0.84 | HDAC3 (0.57) | HDAC3HDAC11HDAC8HDAC6DEGS1 | |
| SCHEMBL1749356 | 0.83 | MCHR1 (0.70) | HDAC3HDAC11HDAC8HDAC6DEGS1 | |
| SCHEMBL1749354 | 0.83 | MCHR1 (0.70) | HDAC3HDAC11HDAC8HDAC6DEGS1 | |
| SCHEMBL12529199 | 0.82 | MCHR1 (0.70) | HDAC3HDAC11HDAC8HDAC6DEGS1 | |
| SCHEMBL14113483 | 0.81 | KDM1A (0.67) | HDAC3HDAC11HDAC8HDAC6DEGS1 | |
| SCHEMBL1750064 | 0.80 | MCHR1 (0.71) | HDAC3HDAC11HDAC8HDAC6DEGS1 | |
| SCHEMBL1750063 | 0.79 | MCHR1 (0.53) | HDAC3HDAC11HDAC8HDAC6DEGS1 | |
| SCHEMBL12529486 | 0.79 | HDAC3 (0.53) | HDAC3HDAC11HDAC8HDAC6DEGS1 | |
| SCHEMBL12529484 | 0.76 | MCHR1 (0.58) | HDAC3HDAC11HDAC8HDAC6DEGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| EP-1597228-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| WO-2004072025-A2 | SUBSTITUTED N-ARYLHETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | HDAC3 2372/4885HDAC11 2569/4885HDAC8 3207/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | HDAC3 2248/4885HDAC11 2877/4885HDAC8 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.